Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
- 17 September 2022
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 58, 101014
Abstract
No abstract availableKeywords
This publication has 103 references indexed in Scilit:
- The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic LeukemiaMedicine, 2013
- High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effectsJournal of Allergy and Clinical Immunology, 2013
- Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeHaematologica, 2012
- Response of ETV6-FLT3–positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3Blood, 2011
- Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemiaCancer Chemotherapy and Pharmacology, 2011
- Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndromeJournal of Allergy and Clinical Immunology, 2010
- Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapyJournal of Allergy and Clinical Immunology, 2009
- Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingBlood, 2007
- Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinationsBlood, 2006
- Treatment of hypereosinophilic syndrome with imatinib mesilateThe Lancet, 2002